NEPHROLOGY COMPREHENSIVE EXAM - KDIGO 2026 /
ABIM-ESENEPH BLUEPRINT - 2026/2027 EDITION - 120
COMPREHENSIVE QUESTIONS WITH VERIFIED ANSWERS
169 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NEPHROLOGY COMPREHENSIVE EXAM - KDIGO 2026 / ABIM-ESENEPH BLUEPRINT - 2026/2027 EDITION
- 120 COMPREHENSIVE QUESTIONS WITH VERIFIED ANSWERS. It contains 169 carefully selected questions
that reflect the most current exam content and testing strategies. Each question is accompanied by a correct
answer and a detailed rationale that explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 169 Questions
Foundations - Application - Nephrology Comprehensive Kdigo 2026 / ABIM Eseneph Blueprint 2026/2027
Edition 120 Comprehensive WITH Nephrology Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Nephrology Comprehensive 1-29 Kidney, Appropriate, According, Kdigo, Disease
Kdigo 2026 / ABIM Eseneph
Blueprint 2026/2027 Edition
120 Comprehensive WITH
Nephrology Graduate
Disease 30-58 Kidney, Acute, Serum, Kdigo, Appropriate
Appropriate 59-87 Kidney, Disease, Kdigo, According, Finding
Kdigo 88-116 Kidney, Disease, Acute, Appropriate, Therapy
Serum 117-145 Kidney, Disease, Strongly, Acute, Appropriate
Acute 146-169 Kidney, Disease, Chronic, Renal, Appropriate
TOTAL 169 All questions include answers and detailed rationales
,Section A - Nephrology Comprehensive Kdigo 2026 / ABIM
Eseneph Blueprint 2026/2027 Edition 120 Comprehensive
WITH Nephrology Graduate
Q1.
In a patient with anti-GBM disease, which combination of findings on renal biopsy most
strongly predicts poor renal recovery despite aggressive plasmapheresis?
A. Diffuse crescentic glomerulonephritis with B. Focal segmental glomerulosclerosis with
>50% crescents and linear IgG staining foot process effacement
C. Membranoproliferative pattern with D. Minimal change disease with normal
subendothelial deposits immunofluorescence
Correct: A - Diffuse crescentic glomerulonephritis with >50% crescents and linear IgG
staining
Rationale:In anti-GBM disease, the presence of >50% crescents and linear IgG staining
indicates severe, irreversible glomerular injury, portending poor renal recovery. Other patterns
(FSGS, MPGN, MCD) are not typical of anti-GBM disease and carry different prognoses.
Q2.
A patient with autosomal dominant polycystic kidney disease (ADPKD) has rapid kidney
growth and declining eGFR. Which therapeutic strategy is most appropriate to slow
progression, according to KDIGO 2026?
A. Initiate tolvaptan and maintain high water B. Start ACE inhibitor and restrict dietary
intake protein to 0.6 g/kg/day
C. Prescribe metformin for its anti-fibrotic D. Recommend bilateral nephrectomy
effects before ESRD
Correct: A - Initiate tolvaptan and maintain high water intake
Rationale:Tolvaptan, a vasopressin V2 receptor antagonist, is the only disease-modifying
therapy that slows cyst growth and eGFR decline in ADPKD, especially in rapidly progressive
disease. High water intake suppresses vasopressin, but tolvaptan is required for efficacy.
ACE inhibitors and protein restriction are adjunctive but not primary disease-modifying.
Metformin is investigational; nephrectomy is reserved for complications.
Q3.
Which of the following best explains the mechanism of action of SGLT2 inhibitors in
conferring renoprotection in diabetic kidney disease?
Page 3
, Section A - Nephrology Comprehensive Kdigo 2026 / ABIM Eseneph Blueprint 2026/2027 Edition 120 Comprehensive WITH Nephrology
Graduate
A. Reduction of intraglomerular pressure via B. Inhibition of the
tubuloglomerular feedback renin-angiotensin-aldosterone system
C. Direct anti-inflammatory effects on D. Increased urinary ammonia excretion to
mesangial cells correct metabolic acidosis
Correct: A - Reduction of intraglomerular pressure via tubuloglomerular feedback
Rationale:SGLT2 inhibitors reduce proximal sodium reabsorption, increasing distal sodium
delivery, which activates tubuloglomerular feedback, leading to afferent arteriolar
vasoconstriction and reduced intraglomerular hypertension. This is the primary mechanism for
renoprotection. They do not directly block RAAS, though they may modulate it;
anti-inflammatory effects are secondary; they do not primarily alter ammonia excretion.
Q4.
A patient with suspected acute interstitial nephritis (AIN) has a urine sediment showing
white blood cell casts and eosinophiluria. Which additional finding would most strongly
support AIN over acute tubular necrosis (ATN)?
A. Fractional excretion of sodium >2% B. Presence of renal tubular epithelial cell
casts
C. Fever, rash, and peripheral eosinophilia D. Urine osmolality >500 mOsm/kg
Correct: C - Fever, rash, and peripheral eosinophilia
Rationale:The classic triad of fever, rash, and eosinophilia is highly specific for drug-induced
AIN, whereas ATN typically lacks these systemic features. FE Na >2% and tubular casts can
be seen in both. Urine osmolality >500 suggests preserved concentrating ability, which is
more typical of prerenal, not AIN or ATN.
Q5.
In a hemodialysis patient with serum phosphate 7.2 mg/dL and calcium 8.0 mg/dL, which
of the following is the most appropriate initial management according to KDIGO 2026?
A. Start sevelamer carbonate and restrict B. Administer intravenous calcium gluconate
dietary phosphate immediately
C. Increase dialysis frequency to daily D. Prescribe calcitriol to lower PTH
sessions
Correct: A - Start sevelamer carbonate and restrict dietary phosphate
Page 4
ABIM-ESENEPH BLUEPRINT - 2026/2027 EDITION - 120
COMPREHENSIVE QUESTIONS WITH VERIFIED ANSWERS
169 Questions with Answers and Detailed Rationales
100 PERCENT GUARANTEED PASS
INSTANT DOWNLOAD ANSWERS INCLUDED
IMPORTANCE OF THIS DOCUMENT
This comprehensive examination preparation guide has been meticulously developed to help you succeed in the
NEPHROLOGY COMPREHENSIVE EXAM - KDIGO 2026 / ABIM-ESENEPH BLUEPRINT - 2026/2027 EDITION
- 120 COMPREHENSIVE QUESTIONS WITH VERIFIED ANSWERS. It contains 169 carefully selected questions
that reflect the most current exam content and testing strategies. Each question is accompanied by a correct
answer and a detailed rationale that explains the underlying pathophysiology, pharmacology, or clinical reasoning.
Self-Assessment – Test your knowledge and Exam Preparation – Familiarize yourself with the
identify areas requiring further question format and content
study areas
Concept Reinforcement – Deepen your Confidence Building – Develop test-taking
understanding through strategies and reduce
evidence-based exam anxiety
rationales
Time Management – Practice answering
questions under simulated
exam conditions
Review Summary 169 Questions
Foundations - Application - Nephrology Comprehensive Kdigo 2026 / ABIM Eseneph Blueprint 2026/2027
Edition 120 Comprehensive WITH Nephrology Graduate
All answers with rationales
,Table of Contents
Content Area Questions Key Topics
Nephrology Comprehensive 1-29 Kidney, Appropriate, According, Kdigo, Disease
Kdigo 2026 / ABIM Eseneph
Blueprint 2026/2027 Edition
120 Comprehensive WITH
Nephrology Graduate
Disease 30-58 Kidney, Acute, Serum, Kdigo, Appropriate
Appropriate 59-87 Kidney, Disease, Kdigo, According, Finding
Kdigo 88-116 Kidney, Disease, Acute, Appropriate, Therapy
Serum 117-145 Kidney, Disease, Strongly, Acute, Appropriate
Acute 146-169 Kidney, Disease, Chronic, Renal, Appropriate
TOTAL 169 All questions include answers and detailed rationales
,Section A - Nephrology Comprehensive Kdigo 2026 / ABIM
Eseneph Blueprint 2026/2027 Edition 120 Comprehensive
WITH Nephrology Graduate
Q1.
In a patient with anti-GBM disease, which combination of findings on renal biopsy most
strongly predicts poor renal recovery despite aggressive plasmapheresis?
A. Diffuse crescentic glomerulonephritis with B. Focal segmental glomerulosclerosis with
>50% crescents and linear IgG staining foot process effacement
C. Membranoproliferative pattern with D. Minimal change disease with normal
subendothelial deposits immunofluorescence
Correct: A - Diffuse crescentic glomerulonephritis with >50% crescents and linear IgG
staining
Rationale:In anti-GBM disease, the presence of >50% crescents and linear IgG staining
indicates severe, irreversible glomerular injury, portending poor renal recovery. Other patterns
(FSGS, MPGN, MCD) are not typical of anti-GBM disease and carry different prognoses.
Q2.
A patient with autosomal dominant polycystic kidney disease (ADPKD) has rapid kidney
growth and declining eGFR. Which therapeutic strategy is most appropriate to slow
progression, according to KDIGO 2026?
A. Initiate tolvaptan and maintain high water B. Start ACE inhibitor and restrict dietary
intake protein to 0.6 g/kg/day
C. Prescribe metformin for its anti-fibrotic D. Recommend bilateral nephrectomy
effects before ESRD
Correct: A - Initiate tolvaptan and maintain high water intake
Rationale:Tolvaptan, a vasopressin V2 receptor antagonist, is the only disease-modifying
therapy that slows cyst growth and eGFR decline in ADPKD, especially in rapidly progressive
disease. High water intake suppresses vasopressin, but tolvaptan is required for efficacy.
ACE inhibitors and protein restriction are adjunctive but not primary disease-modifying.
Metformin is investigational; nephrectomy is reserved for complications.
Q3.
Which of the following best explains the mechanism of action of SGLT2 inhibitors in
conferring renoprotection in diabetic kidney disease?
Page 3
, Section A - Nephrology Comprehensive Kdigo 2026 / ABIM Eseneph Blueprint 2026/2027 Edition 120 Comprehensive WITH Nephrology
Graduate
A. Reduction of intraglomerular pressure via B. Inhibition of the
tubuloglomerular feedback renin-angiotensin-aldosterone system
C. Direct anti-inflammatory effects on D. Increased urinary ammonia excretion to
mesangial cells correct metabolic acidosis
Correct: A - Reduction of intraglomerular pressure via tubuloglomerular feedback
Rationale:SGLT2 inhibitors reduce proximal sodium reabsorption, increasing distal sodium
delivery, which activates tubuloglomerular feedback, leading to afferent arteriolar
vasoconstriction and reduced intraglomerular hypertension. This is the primary mechanism for
renoprotection. They do not directly block RAAS, though they may modulate it;
anti-inflammatory effects are secondary; they do not primarily alter ammonia excretion.
Q4.
A patient with suspected acute interstitial nephritis (AIN) has a urine sediment showing
white blood cell casts and eosinophiluria. Which additional finding would most strongly
support AIN over acute tubular necrosis (ATN)?
A. Fractional excretion of sodium >2% B. Presence of renal tubular epithelial cell
casts
C. Fever, rash, and peripheral eosinophilia D. Urine osmolality >500 mOsm/kg
Correct: C - Fever, rash, and peripheral eosinophilia
Rationale:The classic triad of fever, rash, and eosinophilia is highly specific for drug-induced
AIN, whereas ATN typically lacks these systemic features. FE Na >2% and tubular casts can
be seen in both. Urine osmolality >500 suggests preserved concentrating ability, which is
more typical of prerenal, not AIN or ATN.
Q5.
In a hemodialysis patient with serum phosphate 7.2 mg/dL and calcium 8.0 mg/dL, which
of the following is the most appropriate initial management according to KDIGO 2026?
A. Start sevelamer carbonate and restrict B. Administer intravenous calcium gluconate
dietary phosphate immediately
C. Increase dialysis frequency to daily D. Prescribe calcitriol to lower PTH
sessions
Correct: A - Start sevelamer carbonate and restrict dietary phosphate
Page 4
